Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $43,451.00 |
|---|---|
| Enterprise Value | $153,118.00 |
| Earnings per Share | $-0.26 |
| Beta | -3.06 |
| Outstanding Shares | 434,436,861 |
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.91 |
| Debt to Equity | -0.73 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorder...